SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MGI Pharma MOGN New patents, anti cancer
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mark Oliver who wrote ()10/21/1996 9:30:00 PM
From: JoeG   of 1826
 
Some interesting news for MGI out today.Here's an excerpt from the news release :

Frederick B. Vivino, M.D., Medical Director of the Philadelphia Sjogren's
Syndrome and Dry Mouth Treatment Center at the Presbyterian Medical Center,
University of Pennsylvania Health System, presented the new data at the
Rheumatology conference. In discussing the potential impact of Salagen(R)
Tablets, Dr. Vivino stated, "The data I presented in Orlando showed that if
Sjogren's patients receive an initial benefit from Salagen(R) Tablets, they
can expect to experience continued benefit with safety over the long-term.
Should the results from the broader study support these early findings,
Salagen(R) Tablets could represent the most exciting breakthrough for
Sjogren's Syndrome patients since the discovery of anti-SSA antibodies (a
diagnostic test for Sjogren's Syndrome) in the 1970's."

For the complete story:

prnewswire.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News